KPV
Lysine-Proline-Valine
KPV is a peptide people usually talk about for Inflammatory bowel disease and Intestinal inflammation. It is still in the FDA review process, so people are watching both the research and the access question closely.
Why does this matter?
KPV matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.
Molecular weight
342.43 g/mol
Molecular formula
C₁₆H₃₀N₄O₄
Amino acid count
3
Review date
July 23-24, 2026
Sequence / structure
Lys-Pro-Val (positions 11-13 of α-MSH)
Other names
KPV tripeptide, α-MSH (11-13), Alpha-MSH C-terminal tripeptide, Lys-Pro-Val
Status
Under FDA review for wound healing and inflammatory conditions
KPV is a tiny peptide fragment taken from a natural hormone your body already makes. Even though it is only three amino acids long, it is known for calming inflammation in the gut, on the skin, and around healing tissue without the tanning effects of the full parent hormone. That is why it gets so much attention for inflammatory bowel disease, irritated skin, and wound repair.
The quick version before the deep dive
- •People usually talk about KPV for Inflammatory bowel disease and Intestinal inflammation.
- •Intestinal inflammation.
- •Directly enters cells and inhibits NF-κB activation in the nucleus, blocking the master inflammatory transcription pathway.
- •Helps lower TNF-α, IL-1β, IL-6, and other pro-inflammatory mediators.
Deep Dive: Mechanism of Action +
NF-κB Inhibition — Directly enters cells and inhibits NF-κB activation in the nucleus, blocking the master inflammatory transcription pathway
Anti-inflammatory Cytokine Suppression — Reduces TNF-α, IL-1β, IL-6, and other pro-inflammatory mediators
Antimicrobial Activity — Direct bactericidal effects against Staphylococcus aureus, Candida albicans, and other pathogens
Transepithelial Transport — Can cross intestinal epithelium intact, enabling oral bioavailability for GI conditions
MAP Kinase Modulation — Inhibits p38 and JNK inflammatory signaling cascades
Immune Cell Modulation — Reduces neutrophil and macrophage inflammatory activation
Does NOT activate melanocortin receptors — Anti-inflammatory effects are receptor-independent (intracellular mechanism)
Where people usually see it discussed
Gastrointestinal +
- Inflammatory bowel disease (Crohn's, ulcerative colitis)
- Intestinal inflammation
- Mucosal healing
- Gut barrier restoration
Dermatological +
- Wound healing (FDA review indication)
- Atopic dermatitis/eczema
- Psoriasis
- Contact dermatitis
- Post-surgical healing
- Acne and inflammatory skin conditions
Antimicrobial +
- Skin infections
- Mucosal infections
- Biofilm disruption
Other Inflammatory Conditions +
- Allergic inflammation
- Arthritis (preclinical)
- Neuroinflammation
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
Catania et al. (multiple)
PreclinicalColitis models
Significant reduction in inflammation scores
Dalmasso et al. 2008
PreclinicalIBD (oral nanoparticles)
Oral KPV-loaded nanoparticles reduced colitis
Luger et al.
PreclinicalDermatitis
Topical KPV reduced inflammatory skin lesions
Brzoska et al.
PreclinicalWound healing
Accelerated wound closure, reduced scarring
What the current safety discussion looks like
- ✓Derived from endogenous hormone — α-MSH is naturally produced in the body
- ✓No melanogenic effects — Unlike full α-MSH or Melanotan, KPV does not cause tanning
- ✓No reported serious adverse effects in preclinical studies
- ✓High therapeutic index — effective at very low doses
- ✓Theoretical concerns: None significant due to its endogenous origin and minimal off-target activity
- ✓Does not bind melanocortin receptors — avoids the side effect profile of MCR agonists
How the status timeline currently reads
Pre-2023
Category 1 — eligible for 503A compounding
September 2023
Moved to Category 2
April 2026
FDA announces PCAC review
July 23-24, 2026
Advisory committee review for wound healing and inflammatory conditions
How dosing is usually described
Subcutaneous
Systemic inflammation: 200-500 mcg/day Duration: 4-8 weeks typical protocols
Oral
GI inflammation: 200-500 mcg/day (capsule) Nanoparticle delivery systems under development for enhanced GI targeting
Topical
Skin conditions: Cream/gel formulations (concentration varies) Applied directly to affected areas
Intranasal
Experimental: For neuroinflammatory conditions
Research protocols only. Not medical advice.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Catania A, et al.*. "The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro." Peptides 1996.
- 2
Brzoska T, et al.*. "α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects." Endocrine Reviews 2008.
- 3
Dalmasso G, et al.*. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology 2008.
- 4
Kannengiesser K, et al.*. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflammatory Bowel Diseases 2008.
- 5
Catania A, et al.*. "Targeting melanocortin receptors as a novel strategy to control inflammation." Pharmacological Reviews 2004.
- 6
Luger TA, et al.*. "New insights into the functions of alpha-MSH and related peptides in the immune system." Annals of the New York Academy of Sciences 2003.
- 7
Xiao B, et al.*. "Nanoparticles with surface antibody against CD98 and carrying KPV tripeptide for oral treatment of colitis." Biomaterials 2014.
Common questions about KPV
What is KPV? +
KPV is Lysine-Proline-Valine, one of the peptides currently under review in connection with wound healing and inflammatory conditions.
What is KPV being reviewed for? +
The current advisory review focuses on wound healing and inflammatory conditions, with a listed review date of July 23-24, 2026.
Which category does KPV belong to? +
KPV is grouped in this library under Healing.
How many amino acids are in KPV? +
KPV is presented here as a 3-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for KPV? +
Lys-Pro-Val (positions 11-13 of α-MSH).
What research applications are most associated with KPV? +
Inflammatory bowel disease, Intestinal inflammation, Mucosal healing, and Gut barrier restoration
How is KPV described as working in the current research? +
Directly enters cells and inhibits NF-κB activation in the nucleus, blocking the master inflammatory transcription pathway. Helps lower TNF-α, IL-1β, IL-6, and other pro-inflammatory mediators.
How is KPV usually discussed in protocols or treatment plans? +
KPV is most often described with subcutaneous and oral protocols in the source material.
What does the safety discussion say about KPV? +
Derived from endogenous hormone — α-MSH is naturally produced in the body No melanogenic effects — Unlike full α-MSH or Melanotan, KPV does not cause tanning
Continue the comparison
BPC-157
BPC-157 is a peptide people usually talk about for Ulcerative colitis and Inflammatory bowel disease. It is still in the FDA review process, so people are watching both the research and the access question closely.
LL-37
LL-37 is a peptide people usually talk about for Infections: Potential treatment for various bacterial, fungal, and viral infections, especially those resistant to conventional antibiotics. and Wound Healing: Application in chronic, non-healing wounds, such as diabetic foot ulcers.. It is still in the FDA review process, so people are watching both the research and the access question closely.
GHK-Cu
GHK-Cu is a peptide people usually talk about for Skin Rejuvenation: Improves skin elasticity, firmness, and thickness while reducing wrinkles, hyperpigmentation, and photodamage. and Wound Healing: Accelerates the healing of chronic wounds, surgical incisions, and burns by promoting tissue remodeling and angiogenesis.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Get notified when KPV becomes available
Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.